# OnCo record nci-anetumab-pembrolizumab-mpm (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nci-anetumab-pembrolizumab-mpm/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nci-anetumab-pembrolizumab-mpm", "NCT03126630" ;
  schema:name "Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)"@en ;
  schema:description "The one trial still testing an antibody-drug conjugate in mesothelioma, combining it with PD-1 blockade on the theory that payload-induced cell death primes an immune response."@en ;
  schema:url <https://onco.cc/trials/nci-anetumab-pembrolizumab-mpm/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03126630> ;
  onco:status "active" ;
  onco:tag "owner-request" ;
  onco:phase "1/2" ;
  schema:startDate "2018-10-04" ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/mesothelin/> ;
  onco:drugs <https://onco.cc/drugs/anetumab-ravtansine/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:institutions <https://onco.cc/institutions/nci/> .